.png)
.png)
CJC-1295 NO DAC + Ipamorelin
Research Hub
RESEARCH MATURITY
RESEARCH FOCUS
Growth Hormone Signalling
Pituitary Regulation
Neuroendocrine Signalling
Receptor Biology
Overview
Mechanism
Research Evidence
Studies
Application
Research Protocols
Safety
References
OVERVIEW
BPC-157 Research Overview
CJC-1295 No DAC and Ipamorelin are two synthetic peptides studied for their ability to influence the body's natural growth hormone signalling system. The term No DAC refers to a shorter-acting form commonly described as modified GRF(1–29), rather than the longer-acting CJC-1295 molecule used in certain clinical studies. Ipamorelin works through a different receptor involved in growth hormone release. Their combination has attracted interest in growth hormone regulation, metabolic signalling, and the biological processes associated with tissue maintenance.
Research has explored how these two peptide types interact with separate signalling pathways that help control growth hormone release. One pathway responds to growth hormone-releasing hormone, while the other responds to signals associated with ghrelin, a hormone also involved in appetite regulation. Because these systems work together in normal physiology, researchers have investigated how activating different pathways can influence growth hormone secretion.
Related growth hormone-releasing peptides have been studied through laboratory experiments, animal research, and selected human investigations. Research involving CJC-1295 with DAC has demonstrated prolonged effects on growth hormone-related measurements, while separate studies have examined the hormone-releasing properties of ipamorelin. However, these findings should not be treated as direct clinical evidence for the specific CJC-1295 No DAC and ipamorelin combination.
Although the underlying growth hormone pathways are well understood, the combined formulation has limited direct human clinical evidence. Changes in hormone levels do not automatically establish improvements in muscle growth, recovery, body composition, or healthy aging. Additional research is needed to clarify the combined effects, safety, and clinical significance of these investigational materials.
Receptor Biology
Growth Hormone Signalling
Examines how **GHRH receptor and ghrelin receptor signalling** separately influence growth hormone release, while the endocrine effects of the exact combined formulation remain insufficiently studied.
Pituitary Regulation
Neuroendocrine Signalling
Classification
Dual Growth Hormone Secretagogue Blend
Copy
QUICK FACTS
29 + 5 amino acids
SEQUENCE
3,367.9 + 711.9 g/mol
MOLECULAR WEIGHT
MOLECULAR FORMULA
RESEARCH STATUS
RESEARCH STATUS
How BPC-157 is being investigated at the cellular and signalling level.
MECHANISM OF ACTION
EVIDENCE AT A GLANCE
The CJC-1295 No DAC and ipamorelin combination is associated with research into two distinct growth hormone signaling pathways. Related GHRH analogues and ipamorelin have been investigated separately, including studies examining hormone-release responses. However, evidence from individual compounds cannot establish the effects of this specific combination, and direct, well-controlled clinical research on the blend remains insufficient.
RESEARCH EVIDENCE
Add paragraph text.
STUDIES REVIEWED
Preclinical research across in vitro and animal models
Add paragraph text.
RESEARCH HISTORY
Research spanning several decades with continued investigation
EVIDENCE MATURITY
Predominantly preclinical evidence with limited human research
EVIDENCE CONTEXT
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Proposed Mechanism
This combination brings together two peptides associated with growth hormone signaling. The material commonly called CJC-1295 No DAC is generally described as a modified growth hormone-releasing hormone fragment, while ipamorelin is a growth hormone secretagogue that acts through a different receptor system.
The GHRH-related component is intended to interact with receptors that normally respond to growth hormone-releasing hormone. Ipamorelin acts through the growth hormone secretagogue receptor, also called GHSR1a. Both pathways can influence growth hormone release from the pituitary gland, but they begin with different biological signals.
Researchers have studied these signaling systems separately. Their combined activity cannot be assumed to produce a particular effect, and the exact formulation lacks an established clinical mechanism or demonstrated benefit. The chemical identity of the No DAC component must also be confirmed rather than inferred from its commercial name.
Proposed Visual
PROPOSE RESEARCH PATHWAY
Compound
BIOLOGICAL TARGET
SIGNALLING RESPONSE
RESEARCH OUTCOME
CJC-1295 NO DAC + Ipamorelin
CJC-1295 No DAC and Ipamorelin are two synthetic peptides studied for their ability to influence the body's natural growth hormone signalling system. The term No DAC refers to a shorter-acting form commonly described as modified GRF(1–29), rather than the longer-acting CJC-1295 molecule used in certain clinical studies. Ipamorelin works through a different receptor involved in growth hormone release. Their combination has attracted interest in growth hormone regulation, metabolic signalling, and the biological processes associated with tissue maintenance.
Research has explored how these two peptide types interact with separate signalling pathways that help control growth hormone release. One pathway responds to growth hormone-releasing hormone, while the other responds to signals associated with ghrelin, a hormone also involved in appetite regulation. Because these systems work together in normal physiology, researchers have investigated how activating different pathways can influence growth hormone secretion.
Related growth hormone-releasing peptides have been studied through laboratory experiments, animal research, and selected human investigations. Research involving CJC-1295 with DAC has demonstrated prolonged effects on growth hormone-related measurements, while separate studies have examined the hormone-releasing properties of ipamorelin. However, these findings should not be treated as direct clinical evidence for the specific CJC-1295 No DAC and ipamorelin combination.
Although the underlying growth hormone pathways are well understood, the combined formulation has limited direct human clinical evidence. Changes in hormone levels do not automatically establish improvements in muscle growth, recovery, body composition, or healthy aging. Additional research is needed to clarify the combined effects, safety, and clinical significance of these investigational materials.